Stock FGEN FIBROGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials FibroGen, Inc.

Equities

FGEN

US31572Q8087

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.04 USD +1.96% Intraday chart for FibroGen, Inc. -9.57% +17.34%
Apr. 24 FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting CI
Apr. 15 Faron Pharmaceuticals reappoints former finance chief on interim basis AN

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,742 3,376 1,307 1,505 87.16 103.5 - -
Enterprise Value (EV) 1 3,742 3,376 1,307 1,505 87.16 103.5 103.5 103.5
P/E ratio -48.2 x -17.6 x -4.49 x -5.1 x -0.3 x -0.73 x -1.04 x -1.21 x
Yield - - - - - - - -
Capitalization / Revenue 14.6 x 19.1 x 5.56 x 10.7 x 0.59 x 0.67 x 0.61 x 0.5 x
EV / Revenue 14.6 x 19.1 x 5.56 x 10.7 x 0.59 x 0.67 x 0.61 x 0.5 x
EV / EBITDA -47.9 x -19.9 x -4.78 x -5.18 x -0.34 x -0.77 x -1.1 x -1.22 x
EV / FCF -44,303,163 x 43,495,355 x -14,953,559 x -10,056,537 x - - - -
FCF Yield -0% 0% -0% -0% - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 87,250 91,011 92,710 93,958 98,340 99,474 - -
Reference price 2 42.89 37.09 14.10 16.02 0.8863 1.040 1.040 1.040
Announcement Date 3/2/20 3/1/21 2/28/22 2/27/23 2/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 256.6 176.3 235.3 140.7 147.8 155.3 169.3 205
EBITDA 1 -78.17 -169.8 -273.7 -290.4 -259.3 -134.8 -94.21 -84.7
EBIT 1 -89.31 -191.9 -288.5 -301 -269.2 -131.7 -34.59 -86.03
Operating Margin -34.81% -108.83% -122.62% -213.9% -182.2% -84.76% -20.43% -41.97%
Earnings before Tax (EBT) 1 -76.64 -188.9 -290.7 -294.9 -286.9 -141.5 -102.4 -88.31
Net income 1 -76.97 -189.3 -290 -293.7 -284.2 -141.5 -102.4 -88.31
Net margin -30% -107.36% -123.25% -208.66% -192.37% -91.11% -60.46% -43.08%
EPS 2 -0.8900 -2.110 -3.140 -3.140 -2.920 -1.415 -1.000 -0.8600
Free Cash Flow -84.47 77.61 -87.42 -149.7 - - - -
FCF margin -32.92% 44.02% -37.15% -106.35% - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/2/20 3/1/21 2/28/22 2/27/23 2/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 156 16.54 60.83 29.81 15.74 34.37 36.16 44.32 40.13 27.14 36.45 37.45 41.47 37.68
EBITDA 53.56 -132.7 -60.41 -75.57 -90.98 - -73.13 - - - - - - -
EBIT 1 50.97 -135.2 -62.99 -78.22 -93.66 -66.15 -76.09 -88.05 -50.88 -54.2 -40.42 -39.14 -32.4 -33.59
Operating Margin 32.68% -817.51% -103.56% -262.44% -595.21% -192.48% -210.42% -198.67% -126.77% -199.71% -110.91% -104.51% -78.13% -89.15%
Earnings before Tax (EBT) 49.56 -134.3 -63.41 -73.17 -91.94 -66.35 -77.43 -88.46 -64.21 - - - - -
Net income 49.8 -134.1 -63.2 -72.62 -91.65 -66.18 -76.7 -87.68 -63.62 - - - - -
Net margin 31.93% -810.49% -103.91% -243.66% -582.46% -192.55% -212.12% -197.84% -158.51% - - - - -
EPS 2 0.5400 -1.450 -0.6800 -0.7800 -0.9800 -0.7000 -0.8100 -0.9000 -0.6500 -0.5700 -0.5300 -0.4800 -0.3700 -0.4100
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/9/21 2/28/22 5/9/22 8/8/22 11/7/22 2/27/23 5/8/23 8/7/23 11/6/23 2/26/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -84.5 77.6 -87.4 -150 - - - -
ROE (net income / shareholders' equity) - -40.4% -91.9% -255% - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share 2 - 0.9100 -0.8900 -1.560 3.240 -0.1500 0.0100 -
Capex 5.76 3.99 5.19 3.74 - - - -
Capex / Sales 2.25% 2.27% 2.2% 2.66% - - - -
Announcement Date 3/2/20 3/1/21 2/28/22 2/27/23 2/26/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for FibroGen, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
3
Last Close Price
1.04 USD
Average target price
1.75 USD
Spread / Average Target
+68.27%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
FIBROGEN, INC. Stock FibroGen, Inc.
+17.34% 103M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. FGEN Stock
  4. Financials FibroGen, Inc.